Facebook Pixel Code
About Sickkids
About SickKids

Meredith Irwin, MD

The Hospital for Sick Children

Research Institute
Senior Scientist
Cell Biology

University of Toronto
Departments of Paediatrics, Medical Biophysics and Laboratory Medicine & Pathobiology

Chair Positions

Children's Oncology Group
Chair, Neuroblastoma Biology Subcommittee

Canadian Institutes of Health Research
Chair, Cancer Progression and Therapeutics Panel

ENACT (Enabling Clinical Translation)

Other Positions

Advances in Neuroblastoma Research

International Neuroblastoma Risk Group Committee

Phone: 416-813-7654 ext. 302912
Fax: 416-813-5327
Email: meredith.irwin@sickkids.ca
Alternate Contact: Meagan Cameira
Alternate Phone: 416-813-5792
Alternate Email: meagan.cameira@sickkids.ca

For more information, visit:

SickKids Kids Cancer Sequencing (KiCS) Program

MIBG Therapy

NAIT Program

SickKids ENACT Committee

Meredith Irwin Lab

Brief Biography

Dr. Irwin received her Bachelors of Science at the Massachusetts Institute of Technology and Medical Degree from Harvard Medical School. She completed residency and fellowship training in paediatrics and Haematology/Oncology at Boston Children’s Hospital and Dana-Farber Cancer Institute at Harvard Medical School in Boston, Massachusetts followed by a research fellowship in the laboratory of Dr. William Kaelin, a Howard Hughes Medical Investigator at the Dana-Farber Cancer Institute studying the role of the p53-related genes, p73 and p63, in cancer.  After three years on faculty at Dana-Farber Cancer Institute, Dr. Irwin joined the Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) in April 2002 as a Clinician-Scientist.

She is currently a Senior Scientist in Cell Biology, Professor of Paediatrics (cross-appointed to the Departments of Laboratory Medicine and Pathobiology (LMP), Medical Biophysics (MBP)) and the Associate Chair for Paediatrics (Research). She also holds many leadership roles in international committees including the Children’s Oncology Group (COG), International Neuroblastoma Risk Group (INRG), and Advances in Neuroblastoma Research (ANR).

Areas of Specialty:

Neuroblastoma, Solid Tumours, Precision Medicine

Clinical Care Activities:

Dr. Irwin is the SickKids Site PI for many COG and New Approaches to Neuroblastoma Therapy (NANT) studies for patients with neuroblastoma and has leadership roles in the COG and INRG.  She was formerly  the Head of the Solid Tumour Section and specialized in the care of patients with newly diagnosed and relapsed neuroblastoma.

Research Interests

Dr. Irwin's laboratory research focuses on understanding the molecular determinants of neuroblastoma to identify novel therapies that target signaling pathways using a variety of cellular and animal models. Their translational research program is linked with the SickKids Kids Cancer Sequencing (KiCS) Program and national precision oncology for young people (PROFYLE) programs, with a focus on modeling novel germline and somatic variants. Dr. Irwin’s research has been funded by Canadian Institutes of Health Research (CIHR), Canadian Cancer Society Research Institute (CCSRI), National Cancer Institute (NCI) and many neuroblastoma-focused foundations.

In addition to laboratory-based research she is involved in international efforts to develop risk classification systems and clinical trials for newly diagnosed and relapsed neuroblastoma. Locally, Dr. Irwin established the Neuroblastoma Program that is co-led by Dr. Daniel Morgenstern and includes a multidisciplinary team with expertise in the care of neuroblastoma patients. The program cares for local patients as well as provides expert consultations and access to local and international clinical trials and MIBG therapy.

As well as translational neuroblastoma research, Dr. Irwin is involved in the development of clinician-scientist training and education programs including the first residency research stream in Paediatrics in Canada. She also co-leads the SickKids ENACT committee which provides guidance for and access to innovative research testing and return of results.

  • Role of p53 family genes in cancer and chemotherapy sensitivity
  • Novel pathways and targeted therapies for neuroblastoma
  • Molecular and genetic determinants of metastasis in neuroblastoma
  • Genetic predisposition to Neuroblastoma
  • Prognostic factors and Risk Stratification for Neuroblastoma
  • Precision medicine


For full list of publications, please visit PubMed